ESTRO 2024 - Abstract Book

S303

Brachytherapy - Head & neck, skin, eye

ESTRO 2024

Material/Methods:

Between 01/2010 and 12/2020, 55 patients with T1-2N0 primitive squamous cell carcinomas of the tongue were treated with interstitial low-dose-rate, or pulsed-dose-rate brachytherapy, with or without neck dissection, at the our center. The primary objective was to evaluate the efficacy of brachytherapy in terms of local recurrence-free survival (LRFS). The secondary objectives were to estimate regional recurrence-free survival (RRFS), overall survival (OS), and to describe toxicities of brachytherapy. LRFS, RRFS and OS were estimated using the Kaplan-Meier method from the date of diagnosis. The cumulative incidence of local recurrence was estimated using the Kalbfleisch-Prentice method. The prognostic factors for LRFS were evaluated using multivariable Cox models.

Results:

Local recurrence-free survival (LRFS) rates at 1-year, 3-years, and 5-years follow-up were 90.9%, 62.9%, and 49.4%, respectively. The cumulative incidences of local recurrence at 1-year, 3-years, and 5-years follow-up were 1.8%, 10.2%, and 12.3%, respectively, Regional recurrence-free survival rates at 1-year, 3-years, and 5-years follow-up were 87.3%, 57.2%, and 46.0%, respectively. Overall survival (OS) rates at 1-year, 3-years, and 5-years follow-up were 90.9%, 71.2%, and 53.4%, respectively, with a 95% confidence interval (CI). We identified 14 (25.5%) grade 3 complications and 16 (29.1%) grade 2 complications. Age at diagnosis (p<0.001), smoking (p=0.018), and tumor stage (p=0.009) were found to be significant prognostic factors (p<0.05) for LRFS.

Conclusion:

Brachytherapy is a moderate effective treatment option for early-stage primitive tongue carcinoma. Despite the frequent toxicities generated, this approach offers several notable advantages, including the preservation of oral anatomy and functions, ultimately leading to an improved quality of life for patients.

Keywords: Tongue, interstitial brachytherapy, local control

1556

Poster Discussion

Interstitial, surface and combined techniques of high dose rate brachytherapy for lip cancer

Sang-June Park 1 , Serhii Brovchuk 2,3 , Zoia Shepil 2,4 , Puja Venkat 1 , Jeffrey Demanes 1 , Oleg Vaskevych 2

1 University of California, Department of Radiation Oncology, Los Angeles, USA. 2 Kyiv Regional Oncology Dispensary, Radiotherapy department, Kyiv, Ukraine. 3 LISOD Israeli cancer care hospital, Radiation Oncology, Kyiv, Ukraine. 4 Shalimov National Institute of Surgery and Transplantology, Radiotherapy department, Kyiv, Ukraine

Purpose/Objective:

Due to the short history of use of interstitial (IS) high-dose-rate brachytherapy (HDR-BT) for lip cancer, relatively few studies on HDR have been published. Although, the IS technique has been used for standard HDR-BT for lip cancer, two institutions (Ukraine and USA) considered and evaluated other techniques of HDR-BT for lip cancer